UCI Medical Center Clinical Trials Web Page
Standard Research Recruitment Advertisement Format

Note: This form must be submitted to the IRB for approval either as part of a new protocol application or with a request for modification to an IRB-approved protocol (electronic Protocol Modification (e-mod) Request can be found at www.rgs.uci.edu/hs/mod). When you have received approval from the IRB for the advertisement text, please provide a stamped copy to Leanne Spaide, UCI Medical Center, Marketing and Public Relations Department, Rt. 163A, fax (714) 456-8968, for posting on the www.ucihealth.com clinical trials Web page.

1. Lead Researcher: Christopher Zachary, MBBS FRCP

2. Study Title: A Phase 2, Randomized, Double-Blind, Within-Subject, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-06473871 In Reducing Hypertrophic Skin Scarring

3. Purpose of Study (e.g., to evaluate a new drug for breast cancer): The purpose of this research study is to find out if an investigational injectable medication called PF 06473871 can improve the appearance of scars.

4. Eligibility (e.g., adults on medication for high blood pressure; diabetic patients on insulin; normal, healthy adults; etc.): Presence of bilateral breast scars between the ages of 18 and 55.

5. Location (if other than UCIMC):
University of California, Irvine Dermatology Research, 1001 Hewitt Hall, Irvine CA 92697

6. Time Commitment (e.g., three one-hour long visits in three weeks): If you decide to be in the study and the study doctor says you can be in the study, your participation will last about 24 Weeks. You will have to come to the study center about 9 times during the study.

7. Anticipated Benefits (if any): The study drug may help your scars, but there is no guarantee that being in this study will help you. Your scars might not get better or may even get worse while you are in this study. You will get placebo on one side, which means you will not be receiving active drug on that side. Information from this study might help researchers to come up with new tests or medications to help others in the future.

8. Compensation (if any): You will get a total of up to $800 if you finish the whole study. If you do not finish the whole study, you will get $50 for each Day 1 and Week 1 study visit you finish. You will also get $100 for each Week 5, 11, 18, and 24 study visit you finish and $150 for each Week 2 and 8 study visit you complete. The study doctor or study staff can tell you more about when you will get paid.

9. Contact Name, UCI Department, Phone Number and E-mail:
Brian Swasdibutra
UCI Department of Dermatology
949-824-7103
bswasdib@uci.edu

Signature of Lead Researcher: _____ Date: _____

IRB Approval Granted on: